Decoy Therapeutics is trading at $1.55, down 7.17% in pre-market on October 6; no clearly reported company-specific catalyst has been identified.
- Recent coverage points to an ongoing dilution overhang following the September warrant inducement, but sources do not establish it as the direct cause of the move.
- The broader market is modestly higher, so it does not explain the decline as a broad-market move.
- Recent closes show consecutive losses through October 5.